Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Biohaven Ltd. before investing.

In this article, we go over a few key elements for understanding Biohaven Ltd.’s stock price such as:

• Biohaven Ltd.’s current stock price and volume
• Why Biohaven Ltd.’s stock price changed recently
• Upgrades and downgrades for BHVN from analysts
• BHVN’s stock price momentum as measured by its relative strength

About Biohaven Ltd. (BHVN)

Before we jump into Biohaven Ltd.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Want to learn more about Biohaven Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Biohaven Ltd..

Biohaven Ltd.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Biohaven Ltd.’s stock price was $13.500.

Biohaven Ltd. is down 2.32% from its previous closing price of $13.820.

During the last market session, Biohaven Ltd.’s stock traded between $13.253 and $13.940. Currently, there are approximately 147.62 million shares outstanding for Biohaven Ltd..

Biohaven Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Biohaven Ltd. Stock Price History

Biohaven Ltd.’s (BHVN) price is currently down 9.27% so far this month.

During the month of July, Biohaven Ltd.’s stock price has reached a high of $17.280 and a low of $13.130.

Over the last year, Biohaven Ltd. has hit prices as high as $18.566 and as low as $7.480. Year to date, Biohaven Ltd.’s stock is up 19.57%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Biohaven Ltd. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Biohaven Ltd.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Biohaven Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Biohaven Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Biohaven Ltd. (BHVN) by visiting AAII Stock Evaluator.

Relative Price Strength of Biohaven Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Biohaven Ltd. has a weighted four-quarter relative price strength of 5.45%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Biohaven Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Biohaven Ltd. Stock Price: Bottom Line

As of July 31, 2026, Biohaven Ltd.’s stock price is $13.500, which is down 2.32% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Biohaven Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.